arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ORAGENICS INC

OGEN
$0.49 ▼ -0.01 (-1.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ORAGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -69.4% ↘
FCF / Share $-0.49 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-2.20M
↑ +0.7% —
Operating Margin Operating profit as % of sales
-356.3%
↑ +22.8% —
FCF / Share Free cash flow per share
$-0.49
↑ +3.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Financial Health ↑
7
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 17 years · 67 quarters